Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study Aims: Breast myxoid fibroadenomas (MFAs) are characterized by a distinctive hypocellular myxoid stroma, and occur sporadically or in the context of Carney complex, an inheritable condition caused by PRKAR1A-inactivating germline mutations. Conventional fibroadenomas (FAs) are underpinned by recurrent MED12 mutations in the stromal components of the lesions. The aim of this study was to investigate the genomic landscape of MFAs and compare it with that of conventional FAs. Methods and results: Eleven MFAs from patients without clinical and/or genetic evidence of Carney complex were retrieved. DNA samples of tumour and matching normal tissue were subjected to massively parallel sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay, an assay targeting 410 cancer genes. Genetic alterations detected by MSK-IMPACT were tested in samples in which the stromal and epithelial components were separately laser capture-microdissected. Sequencing revealed no germline PRKAR1A mutations and non-synonymous mutations in six MFAs. Interestingly, in three of the MFAs in which the stromal and epithelial components were separately microdissected, the mutations were found to be restricted to the epithelial rather than the stromal component. The sole exception was a lesion harbouring a somatic truncating PRKAR1A mutation. Upon histological re-review, this case was reclassified as a breast myxoma, consistent with the spectrum of tumous observed in Carney complex patients. In this case, the PRKAR1A somatic mutation was restricted to the stromal component. Conclusion: MFAs lack MED12 mutations, and their stromal components seem not to harbour mutations in the 410 cancer genes tested. Whole-exome and/or whole-genome analyses of MFAs are required to elucidate their genetic drivers.
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Introduction
Breast fibroadenomas (FAs) are lesions characterized by a neoplastic stroma and epithelial elements with intracanalicular or pericanalicular growth patterns. 1 Myxoid FAs (MFAs) constitute a histological subtype of breast FA characterized by a distinctive hypocellular stromal component with abundant myxoid matrix. Less common than conventional FAs, MFAs are known to develop sporadically; however, these lesions have also been associated with Carney complex.
2, 3 Carney complex is an inheritable, autosomal dominant condition caused by inactivating germline mutations of PRKAR1A in approximately two-thirds of cases. [3] [4] [5] [6] This syndrome is characterized by spotty skin pigmentation, endocrine overactivity, and an increased risk of tumour development. The spectrum of tumours associated with Carney complex consists mainly of myxomas, ranging from cutaneous myxomas to cardiac myxomas; psammomatous melanotic schwannomas and pituitary adenomas are also common in this condition. 4, 7 MFAs occur iñ 40% of female Carney complex patients; 3, 7 however, the actual prevalence of MFAs arising in patients with Carney complex has yet to be defined.
Recent studies have elucidated the genomic landscape of conventional FAs. [8] [9] [10] [11] [12] These lesions have been shown to harbour a low mutation burden and highly recurrent mutations of MED12, which are found in~70% of cases. [8] [9] [10] [11] [12] Additional genes mutated in conventional FAs include RARA, FLNA, and ROS1.
11 These studies have also revealed that the mesenchymal but not the epithelial components of FAs harbour the somatic mutations initially identified by tumour bulk sequencing, suggesting that conventional FAs are probably mesenchymal rather than biphasic tumours. 8 The genomic landscape of MFAs, however, has yet to be described.
Because of the clinical association between MFAs and Carney complex, and the fact that a majority of Carney complex patients harbour PRKAR1A germline mutations, we hypothesized that sporadic MFAs might differ from conventional FAs at the genetic level and be underpinned by somatic mutations in PRKAR1A.
To address this hypothesis, we performed massively parallel sequencing analysis of 11 MFAs employing a targeted capture assay including PRKAR1A, and investigated whether the somatic mutations identified in MFAs are present in the stromal or epithelial components of these lesions. Representative sections from 11 MFAs were subjected to microdissection to ensure >80% tumour content, as previously described, [12] [13] [14] and DNA was extracted from microdissected tissue (Doc. S1). In selected cases (MFA2, MFA6, MFA7, and MFA10), the epithelial and stromal components were separately laser capturemicrodissected as previously described 12 (Doc. S1).
Materials and methods
T A R G E T E D M P S DNA samples extracted from 11 MFAs and their matching normal tissue were subjected to targeted capture massively parallel sequencing at the MSKCC Integrated Genomics Operation with the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay, which targets all exons of 410 genes and non-coding regions of selected genes (Doc. S1).
12,13
Massively parallel sequencing data analysis was performed as described previously (Doc. S1). 12, 13 Somatic genetic alterations and their pathogenicity were detected by the use of state-of-the-art algorithms. 6, [15] [16] [17] [18] [19] [20] [21] [22] [23] Cancer genes were defined as those described in any of three cancer gene lists. [24] [25] [26] FACETS, 15 optimized for MSK-IMPACT sequencing assays, was employed to define allele-specific copy number alterations (CNAs), as previously described. 12, 13 S A N G E R S E Q U E N C I N G Hotspot TERT promoter mutations and selected mutations identified by MSK-IMPACT were investigated in the entire cohort of MFAs and/or in the laser capture-microdissected epithelial and stromal components, respectively, by Sanger sequencing, as previously described 9, 27 (Doc. S1).
I M M U N O H I S T O C H E M I S T R Y
Expression of p53 was investigated in one case (MFA2; Doc. S1).
Results

C A S E S
The MFAs included in this study (Table 1) occurred in female patients, with a median age at diagnosis of 42 years (range 33-58 years). Tumour size ranged from 5 to 9 mm. All cases showed low stromal cellularity, and intracanalicular or mixed intracanalicular and pericanalicular growth patterns ( Figure 1 ). Nine patients presented with concurrent carcinoma (Table S1 ). No MFA occurred in a patient known to have Carney complex, or in a carrier of germline PRKAR1A mutation. Two patients were carriers of germline mutations in BRCA1 (MFA4) and CDH1 (MFA7 ; Table S1 ).
M F A S A R E H E T E R O G E N E O U S A T T H E G E N E T I C L E V E L
MSK-IMPACT was employed to identify the repertoire of somatic genetic alterations of MFAs. Sequencing was performed to a median coverage of 5609 (range 269-7459; Table S2 ), and revealed a median of one (range 0-3) somatic mutation per MFA ( Figure 2 ; Table 2 ; Table S3 ). Whilst eight cases harboured at least one synonymous (n = 2) or non-synonymous (n = 6) somatic mutation, three cases lacked somatic mutations. Each case harbouring non-synonymous somatic mutations showed a unique mutational repertoire ( Figure 2 ; Table 2; Table S3 ). Neither recurrent mutations nor any mutation affecting MED12 were identified in the 11 MFAs analysed. MFA6 showed a truncating somatic single-nucleotide variant in PRKAR1A. Single cases harboured pathogenic mutations in known cancer genes, including a hotspot missense TP53 mutation (R248W in MFA2), a PIK3CA mutation (H1047L in MFA10), and a disruptive deletion in PIK3R1 (L347del in MFA7). Distinct cases harboured missense mutations in ASXL1 (R244H in MFA1) and ERCC5 (P714T in MFA7; Figure 2 ; Table 2 , Table S3 ). Given that TERT promoter hotspot mutations have been described in phyllodes tumours, 12, 13, 28 we assessed, by Sanger sequencing, the presence of TERT promoter hotspot mutations in all MFAs included in this study. Confirming the findings obtained with MSK-IMPACT, which showed no TERT genetic alterations in the MFAs analysed here, Sanger sequencing revealed a lack of TERT promoter mutations (data not shown).
Copy number analysis revealed that the majority of MFAs showed a flat copy number profile (Figure 3) , consistent with the literature on conventional FAs. 29, 30 One case (MFA8), however, showed multiple gains and losses with a focal amplification in FLT4 ( Figure S1 ). No significant histological differences were observed between MFA8 and the remaining cases.
MFA6 was found to harbour a somatic loss-of-function, truncating mutation in PRKAR1A (S307*). This observation is consistent with the hypothesis that a subset of MFAs occurring in patients without a clinical history of Carney complex may be driven by somatic rather than germline inactivation of PRKAR1A. Retrospective histological analysis, however, revealed that MFA6 differed histologically from the PRKAR1A-wild-type MFAs. Whilst all cases but MFA6 showed a well-defined interface between the lesions and surrounding stroma and the overt biphasic architecture characteristic of breast fibroepithelial lesions (Figure 1 ), MFA6 was a roundish lesion composed of round to stellate-shaped cells embedded in abundant hypocellular myxoid stroma. The borders of MFA6, which lacked a well-defined interface with the adjacent breast tissue, were focally irregular, with the ASXL1  TP53  MDC1  PRKAR1A  PIK3R1  ERCC5  PIK3CA   MFA1  MFA2  MFA3  MFA6  MFA7  MFA10  MFA4  MFA8  MFA9  MFA11 myxoid matrix dissecting the surrounding stroma. The few distorted ductal structures within MFA6 probably represented entrapped ducts rather than constitutive components of the lesion ( Figure 4A-C) . Taken together, these morphological features led us to reclassify MFA6 as a breast myxoma, a tumour type that is more frequently observed in Carney complex patients. 3, 4, 7 To validate the PRKAR1A somatic mutation identified by MSK-IMPACT in MFA6 and to investigate whether the mutation was present in the stromal cells but absent in the epithelial cells of the probably entrapped ducts, we performed laser capture microdissection and extracted DNA of each component of MFA6 separately. Sanger sequencing confirmed that the PRKAR1A mutation was indeed present in the stromal cells, but absent in the epithelial cells and in the DNA extracted from normal tissue ( Figure 4D-F) . These findings confirm that the PRKAR1A mutation was somatic, and provide evidence to suggest that the stromal but not the epithelial cells constituted the neoplastic component of this lesion. 
S O M A T I C M U T A T I O N S I N K N O W N C A N C E R G E N E S A R E P R E S E N T A T L O W M U T A N T A L L E L E F R A C T I O N S A N D R E S T R I C T E D T O T H E E P I T H E L I A L C O M P O N E N T S O F M F A S
The somatic mutations identified in seven MFAs (excluding MFA6) were found to be present at low mutant allele fractions, consistent with the notion that these mutations were subclonal. To define whether selected mutations identified by MSK-IMPACT (Table 2) were present in the stromal or epithelial cells of MFAs, three cases were subjected to laser capture microdissection. Sanger sequencing performed on the DNA samples extracted from each component separately revealed that mutations affecting TP53 (MFA2), PIK3R1 and ERCC5 (MFA7) and PIK3CA (MFA10) were present in the epithelial components but absent in the stromal cells of the respective cases ( Figure 5A ). Consistent with these results, immunohistochemistry revealed that 30% of epithelial cells, but not stromal cells, of MFA2 expressed high levels of p53 ( Figure 5B ). Taken together, these findings have led us to hypothesize that these mutations were probably subclonal alterations found in the epithelial components of MFAs, and that the stromal components of MFAs lack somatic mutations affecting MED12 or any of the other 409 cancer genes tested.
Discussion
Here, we demonstrate that, unlike conventional FAs, >70% of which harbour MED12 mutations in the stromal (i.e. mesenchymal) components, [8] [9] [10] [11] 31 nonCarney complex-related MFAs lack MED12 mutations, and no somatic mutations affecting the 410 cancer genes included in our sequencing assay are present at high mutant allele fractions. Moreover, apart from the PRKAR1A mutation in MFA6, selected pathogenic mutations affecting known cancer genes were found to be restricted to the epithelial components of these lesions. Mutations in cancer genes, including TP53 32 and RB1, 8 have been previously detected in individual FAs. However, whether these mutations affected the epithelial or stromal cells was not investigated.
Several hypotheses can be advanced to explain our findings, including the notion that the stromal components of MFAs are not neoplastic and potentially reactive to the neoplastic epithelial component. This hypothesis, however, is unlikely to be correct, given that one case showed gene CNAs, consistent with a clonal lesion, and the low mutant allele fractions of the mutations identified in the epithelial components. Arguably the most parsimonious explanation for our observations is that the genetic driver of MFAs was not encompassed by the list of genes surveyed by MSK-IMPACT, and that the somatic mutations identified in the epithelial components of the lesions analysed in this study were subclonal. Consistent with this hypothesis, Sanger sequencing analysis of selected mutations identified by MSK-IMPACT with laser capture-microdissected samples in which the stromal and epithelial components were separately microdissected revealed that the mutations were restricted to the latter, and the Sanger sequencing peaks in the electropherograms support the notion that these mutations were present in a subset of the epithelial cells analysed, consistent with previous descriptions of somatic mutations in non-neoplastic breast tissue. [32] [33] [34] In addition, immunohistochemical analysis of case MFA2, which harboured a TP53 missense hotspot somatic mutation (R248W) of low variant allele fraction (4.11%), demonstrated strong p53 expression in 30% of epithelial cells.
A somatic, loss-of-function mutation in PRKAR1A was detected in and restricted to the stromal cells of MFA6, which was reclassified as a breast myxoma upon histological re-review. Although MFAs have been noted in patients with Carney complex, 3,7 the development of myxomas is more consistent with the spectrum of tumours associated with the disease, and therefore with the somatic inactivation of PRKAR1A. 35, 36 In fact, other terms such as 'breast myxomatosis' have been used to describe breast tumours arising in Carney complex patients. 3 Somatic PRKAR1A mutations may contribute to~30% of tumours of the Carney complex spectrum occurring in patients without other features of Carney complex and without a germline inactivating mutation in PRKAR1A. 6, 37 For instance, recurrent somatic PRKAR1A mutations have been described in cardiac myxomas 38 and melanotic schwannomas, 39 which are tumour types observed in Carney complex patients. 7, 39, 40 PRKAR1A encodes the cAMP-dependent protein kinase type I-a regulatory subunit, and its inactivation induces protein kinase A activation and tumorigenesis. 6, 7, 41 As PRKAR1A is a tumour suppressor gene, biallelic inactivation of PRKAR1A has been documented in tumours of the Carney complex. 39 It has been suggested, however, that PRKAR1A may be haploinsufficient, given that no loss of heterozygosity (LOH) was found in an eyelid myxoma occurring in a patient known to be heterozygous for a common PRKAR1A germline mutation. 42 Our findings of a PRKAR1A mutation with a low mutant allele fraction (Table S2 ) in a breast myxoma are consistent with a heterozygous mutation, and the lack of coupled LOH further supports the notion that loss of one copy of PRKAR1A may be sufficient for myxomagenesis.
This study has several limitations. First, given the lower frequency of MFAs than of conventional FAs, the number of cases analysed here is relatively small. Despite the small sample size, we were able to rule out the presence of MED12 in these lesions, in contrast to their presence in~70% of FAs. Second, no somatic mutation was identified and validated in the stromal components of MFAs. The results of this study are limited to the 410 key cancer genes included in the MSK-IMPACT sequencing assay, so hence we cannot exclude the possibility that genetic alterations in genes not included in this panel, as well as fusion genes or epigenetic changes, may play a role in the development of MFAs. Although MSK-IMPACT includes MED12, RARA, and ROS1, which are genes mutated in FAs, we were unable to sequence FLNA, owing to the limited amount of residual DNA of the MFAs included in this study and the large size of the gene.
Whole-exome sequencing and/or whole-genome sequencing analyses are warranted to determine whether MFAs are driven by somatic mutations affecting a gene other than those included in MSK-IMPACT. Third, our initial hypothesis that MFAs occurring in patients without Carney complex would be underpinned by PRKAR1A mutations was not confirmed. Rather, we demonstrated that only a breast myxoma, initially diagnosed as breast MFA, harboured a PRKAR1A somatic mutation. Together with the known association between breast myxomatosis and Carney complex, 3 our findings suggest that functional inactivation of PRKAR1A in breast stromal cells by germline or somatic genetic events may result in the development of breast myxomas. Moreover, our findings support the neoplastic nature of breast myxomas.
In conclusion, MFAs were found to lack MED12 somatic mutations, and therefore differ from conventional FAs at the genetic level. Moreover, cancer gene mutations detected in MFAs were confined to the epithelium, and, even in the epithelium, these mutations appear to be restricted to a subset of the cells. Therefore, we posit that the stromal components of MFAs may be driven by genetic alterations affecting a gene other than those surveyed by MSK-IMPACT, or that epigenetic alterations in genes not covered in our analyses may contribute to the pathogenesis of MFAs. Further sequencing analyses are warranted to define the genomic landscape of MFAs. A somatic inactivating mutation in PRKAR1A was noteworthy, and detected in a case reclassified as a breast myxoma, a condition sometimes observed in Carney complex. Additional analyses are warranted to assess the prevalence of PRKAR1A mutations in breast myxomas and whether myxoid breast lesions occurring in Carney complex patients are actually best considered to be breast myxomas rather than MFAs.
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